In the worldwide study, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), over 10,000 patients without cancer were randomized to placebo or a neutralizing antibody to IL-1β for treatment of heart disease (51). The gene discussed is IL1B; the disease is cancer.